

Pharmability submits Clinical Trial Application for first-in-human Phase Ib study of TIR-C in atopic dermatitis

Pharmability today announced the submission of a Clinical Trial Application (CTA) for TIR-C, the company's lead drug candidate for atopic dermatitis (eczema). The planned Phase Ib study will evaluate the safety and efficacy of TIR-C and be conducted in Sweden. The submission marks an important milestone in Pharmability's transition from preclinical to clinical-stage development.



STOCKHOLM, SWEDEN, June 5, 2026 –TIR-C is a novel cutaneous immunomodulatory drug candidate designed to target the underlying mechanisms of atopic dermatitis. The planned Phase Ib study will be the first clinical study of TIR-C in patients with atopic dermatitis and is designed to assess its safety and tolerability, as well as to provide an early evaluation of efficacy.

The submission follows the successful completion of the company's GLP toxicology programme, which established a favourable preclinical safety profile for TIR-C across both systemic and dermal assessments. Together with the company's CMC and broader non-clinical work, these results form the regulatory foundation supporting the planned clinical trial.

"The submission of our Clinical Trial Application is a major milestone for Pharmability," says Leo Holmgren, CEO of Pharmability. "It marks the moment our drug candidate moves from the laboratory toward patients. The robust preclinical data package gives us strong confidence as we prepare to evaluate the safety and efficacy of TIR-C in our first-in-human Phase Ib study in atopic dermatitis."

Subject to regulatory and ethical approval, the study will mark the start of the clinical development of TIR-C. Pharmability will provide further updates as the programme progresses.

For more information, please contact:

Leo Holmgren, CEO

Phone: Tfn: +46 70 049 18 42

Email: leo.holmgren@pharmability.com

About Pharmability

Pharmability (formerly TIRmed Pharma) is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company's drug candidate, TIR-C, is a cutaneous oligonucleotide-based treatment that regulates immune responses and targets the disease's underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief while reducing treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options.

Pharmability is headquartered in Stockholm, Sweden. For more information, visit pharmability.com and follow Pharmability on [LinkedIn](#).